Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($0.47), $0.01 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $450 thousand.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.